These findings were corroborated by in-vitro and in-vivo findings demonstrating protection from tau phosphorylation in MIF KO transgenic models of AD [58] and elevated levels of MIF in periphery and CSF of both AD patients with MCI and more severe diseases [62,63]. This evidence concerns the gene MIF and Alzheimer disease.